Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 fosmanogepix versus caspofungin/fluconazole for candidemia or invasive candidiasis
2022-500455-23-00Phase 3Authorised
- Sponsor
- Basilea Pharmaceutica
- Start
- Dec 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of fosmanogepix in candidemia and invasive candidiasis (2 arms), sponsored by Basilea Pharmaceutica. Primary endpoint: Overall response of treatment success at end of study treatment. Planned start Dec 2024; status: authorised.
02
Drugs
fosmanogepix
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on 2022-500455-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500455-23-00.